Our unique size, financial resources and business model allow us to independently fund and manage each in-licensed product for success.

Licensing-in Criteria

Our main therapeutic areas of interest are oncology, cardiology, immunology, metabolic disorders, infectious diseases and central nervous system diseases - all severe, chronic medical conditions.

We also have competence in orphan and niche indications within our therapeutic areas. Products can include both small molecules and exciting biologics such as proteins, peptides and monoclonal antibodies, as well as new chemical entities.

Evaluation & partnering process

We have a systematic, stringent and aggressive but open-minded evaluation process, with the objective of in-licensing up to ten new products in three years. Chosen projects are allocated realistic resources for development.

Portfolio objectives

We aim to have and maintain ten products in clinical development in our portfolio, of which a maximum of 50% are biologicals and 50% oncology products. These products should be first-in-class or best-in-class development candidates with positive in-vivo results.

Our evaluation teams are interested in investigating any drug development candidate in our main therapeutic areas, especially those that have shown promising results in an animal model, although we are prepared to consider earlier stage candidates. We are also interested in licensing-in development products that can benefit from our formulation and drug delivery capabilities.